Insulin Delivery Devices Market Size – By Product (Insulin Pumps, Insulin Pens, Insulin Pen Needles, Insulin Jet Injectors, Insulin Syringes), By End-use & Global Forecast, 2023 – 2032

Insulin Delivery Devices Market Size – By Product (Insulin Pumps, Insulin Pens, Insulin Pen Needles, Insulin Jet Injectors, Insulin Syringes), By End-use & Global Forecast, 2023 – 2032

Insulin Delivery Devices Market Size

Insulin Delivery Devices Market size was valued at around USD 16.9 billion in 2022 and is projected to reach over USD 46.3 billion by 2032 due to the increasing prevalence of diabetes. As per the International Diabetes Federation (IDF) statistics, the number of diabetic patients is projected to reach 700 million by 2045 from 463 million in 2019, indicating 51% surge. As per the World Health Organization, in 2019, diabetes was amongst the leading cause of mortality with an around 1.5 million deaths.

This significant prevalence is primarily owing to the adoption of unhealthy & sedentary lifestyle. As the insulin delivery devices provide an effective and advanced solution for patients to manage diabetes. With the surging patient populace, the industry is projected to experience significant expansion with the increasing preference for these devices pertaining to higher reliability and reduced need for multiple injections. Further, the pervasiveness of diabetes is notably higher in the elderly individuals.

Insulin delivery devices are medical tools designed to administer insulin, a hormone used to regulate blood sugar levels, into the body. These devices are used by individuals with diabetes, particularly those who require insulin therapy to manage their condition. Insulin delivery devices provide a convenient and controlled way to deliver insulin, that is essential for maintaining proper blood glucose levels and preventing complications associated with diabetes.

However, the high cost associated with advanced insulin delivery devices may hinder industry gains by 2032. For instance, an Insulet Omnipod Personal Diabetes Manager costs around USD 800 and the cost of pod is USD 30 that lasts for 3 days. Further, batteries and supplies account for additional costs, thereby increasing the long-term costs associated with the insulin delivery devices. Inadequate reimbursement in certain countries affects its affordability to patients. New insulins are retailed at relatively high prices in comparison with previously available products. Increased prices are due to the use of new manufacturing techniques and the cost associated with the development. Diabetic patients require more than one insulin vial per month that adds to the overall cost of the disease management.

COVID-19 Impact

The COVID-19 arose as an unprecedented public health concern across the globe and had a slight negative impact on the insulin delivery devices market development. The COVID-19 pandemic drastically disrupted the manufacturing and supply chain & logistics, negatively affecting the medical devices sector by restraining the product adoption. Several medical practices including the diabetes care service providers were affected owing to travel restrictions and lockdown implemented by the governing authorities. According to the World Health Organization (WHO), in 2020, approximately half of the countries documented notable disruptions related to diabetic management practices, impacting approximately 49% of such practices.

Diabetic patients suffering from type 1 diabetes (T1D) were more vulnerable and were at a high risk of COVID-19. The use of wearable medical devices comprising tubeless insulin pumps in hospitals had slightly increased in some countries during this pandemic. As per the American Diabetes Association (ADA), as part of the management of type 1 diabetes (T1D) in a patient with coronavirus disease, the use of diabetes technology comprising tubeless insulin pumps was recommended to improve glycemic control. This pandemic had stimulated the adoption of insulin delivery devices in-home care owing to less availability of hospital beds. Several governing authorities including the U.S. had accelerated the authorization of changes in clinical practice to allow teleconsultation.

Insulin Delivery Devices Market Trends

Rising advancements in insulin delivery devices intended to improve the comfort, safety, and overall well-being of individuals suffering from diabetes will spur business evolution. Introduction of digital diabetes management technologies and their integration into insulin delivery devices has offered highly reliable and convenient solutions to patients. Continuous efforts by the organizations for the development of innovative products providing ease in insulin delivery and blood glucose level monitoring with an active lifestyle will accelerate the product adoption.

Further, the launch of bluetooth-enabled wearable devices with continuous glucose monitoring systems has allowed real-time monitoring and insulin delivery at the required stage. For instance, Insulet Corporation received the U.S. FDA approval for the Omnipod DASH Insulin Management System with a bluetooth connectivity, and personal diabetes manager. Bluetooth feature of the system enables connectivity to Omnipod display and Omnipod view apps providing quick access to insulin therapy information to patients as well as professionals on their smartphones.

Insulin Delivery Devices Market Analysis

Based on device type, the insulin delivery devices market is segmented as insulin pumps, insulin pens, insulin pen needles, insulin jet injectors, insulin syringes, and others. The insulin pumps segment is projected to expand at 12.3% CAGR to reach USD 15 billion by 2032 attributable to the multiple benefits related to the use of insulin pens such as affordable price, user-friendly design, and technological advancements among others.

The introduction of new smart insulin pens equipped with Bluetooth or other wireless connectivity, allowing them to connect to smartphone apps has resulted in rising popularity among consumers. These apps can track insulin doses, provide reminders for insulin injections, and help users monitor their insulin regimen and blood sugar levels over time. These devices commonly allow advanced settings, such as dose recommendations, data sharing, and touchscreen interfaces. Data sharing with healthcare providers enables them to modify the treatment to the specific needs of each patient.
 

Based on end-use, the insulin delivery devices market is segmented as home care, hospitals & clinics, and others. The home care settings segment was valued at over USD 9.6 billion in 2022 attributed to the rising patient preference for the use of insulin delivery devices in home care settings, access to user-friendly equipment, and facilitative policies initiated by public associations to promote diabetes self-management.
 

For instance, the American Diabetes Association operates Diabetes Self-Management Support (DSMS) program and recently initiated Diabetes Support Initiative to assist & educate diabetic patients in self-managing the diabetes. Similarly, the Building Community Supports for Diabetes Care initiative offers support to diabetes patients and encourages people to opt for diabetes care at homecare settings, intending to limit the expenses. This increasing trend towards providing diabetes management care in home settings has gained significant popularity, due to factors such as the desire to reduce frequent visits to hospitals, patient convenience, and affordable cost. Insulin delivery devices that are user-friendly, portable, and ideal for home use have experienced an increase in demand.
 

The U.S. insulin delivery devices market is predicted to reach over USD 19 billion by 2032 owing to several variables including the high disease burden of diabetic conditions, the rise in awareness regarding insulin delivery devices, and increasing diabetes care expenditure in the country. For instance, as per the Centers for Disease Control and Prevention, around 1 out of every 4 dollars healthcare costs along with USD 237 billion direct medical cost is spent on diabetes care in the U.S.
 

Insulin Delivery Devices Market Share

Some of the major players operating in the insulin delivery devices market

• Novo Nordisk A/S
• Ypsomed Holdings AG
• Medtronic plc
• Tandem Diabetes Care
• Sanofi
• Biocon
• Eli Lilly & Company
• Insulet Corporation
• Roche
• B Braun Melsungen AG

Insulin Delivery Devices Market Share

• In December 2022, Novo Nordisk and Amalgam expanded partnership on connected insulin delivery devices. The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors and electronic health records.
   
• In August 2021, Insulet Corporation announced FDA approval for using Eli Lilly’s Lyumjev injection with Insulet’s Omnipod Insulin Management System and Omnipod DASH Insulin Management System. This FDA approval helped the company to offer more clinical choices for diabetes patients to manage their glucose levels and limit post-meal elevations.

Insulin delivery devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segm
ents

By Product, 2018 - 2032 (USD Million)

• Insulin pumps
• Tubed/tethered
• Tubeless 
• Insulin pens
• Reusable
• Disposable
• Insulin pen needles
• Safety
• Standards
• Insulin jet injectors
• Insulin syringes
• Others                                             

By End-use, 2018 - 2032 (USD Million)

• Home care
• Hospitals & clinics
• Others  

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Egypt